Trial Profile

A Phase I, Multi-Center, Open-Label, Two-Stage Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMP-224 in a Regimen Containing Cyclophosphamide in Patients with Advanced Solid Malignancies (Amplimmune AMP-224-01).

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AMP 224 (Primary) ; Cyclophosphamide
Indications Malignant melanoma; Ovarian cancer; Solid tumours; T-cell lymphoma
Focus Adverse reactions; First in man
Sponsors Amplimmune

08 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
05 Apr 2013 Data will be presented at the American Association for Cancer Research Annual Meeting 2013, according to a Sarah Cannon Research Institute media release.
24 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com